“NF-κB”的意思、由来-开放百科全书

NF-κB was discovered by Ranjan Sen (NIH) in the lab of Nobel laureate David Baltimore via its interaction with an 11-base pair sequence in the immunoglobulin light-chain enhancer in B cells.^[12]

Structure

All proteins of the NF-κB family share a Rel homology domain in their N-terminus. A subfamily of NF-κB proteins, including RelA, RelB, and c-Rel, have a transactivation domain in their C-termini. In contrast, the NF-κB1 and NF-κB2 proteins are synthesized as large precursors, p105, and p100, which undergo processing to generate the mature NF-κB subunits, p50 and p52, respectively. The processing of p105 and p100 is mediated by the ubiquitin/proteasome pathway and involves selective degradation of their C-terminal region containing ankyrin repeats. Whereas the generation of p52 from p100 is a tightly regulated process, p50 is produced from constitutive processing of p105.^[13]^[14] The p50 and p52 proteins have no intrinsic ability to activate transcription and thus have been proposed to act as transcriptional repressors when binding κB elements as homodimers.^[15]^[16] Indeed, this confounds the interpretation of p105-knockout studies, where the genetic manipulation is removing an IκB (full-length p105) and a likely repressor (p50 homodimers) in addition to a transcriptional activator (the RelA-p50 heterodimer).

Members

NF-κB family members share structural homology with the retroviral oncoprotein v-Rel, resulting in their classification as NF-κB/Rel proteins.^[1]

Species distribution and evolution

In addition to mammals, NF-κB is found in a number of simple animals as well.^[18] These include cnidarians (such as sea anemones, coral and hydra), porifera (sponges), the single-celled eukaryote Capsaspora owczarzaki and insects (such as moths, mosquitoes and fruitflies). The sequencing of the genomes of the mosquitoes A. aegypti and A. gambiae, and the fruitfly D. melanogaster has allowed comparative genetic and evolutionary studies on NF-κB. In those insect species, activation of NF-κB is triggered by the Toll pathway (which evolved independently in insects and mammals) and by the Imd (immune deficiency) pathway.^[19]

Signaling

Effect of activation

NF-κB is important in regulating cellular responses because it belongs to the category of "rapid-acting" primary transcription factors, i.e., transcription factors that are present in cells in an inactive state and do not require new protein synthesis in order to become activated (other members of this family include transcription factors such as c-Jun, STATs, and nuclear hormone receptors). This allows NF-κB to be a first responder to harmful cellular stimuli. Known inducers of NF-κB activity are highly variable and include reactive oxygen species (ROS), tumor necrosis factor alpha (TNFα), interleukin 1-beta (IL-1β), bacterial lipopolysaccharides (LPS), isoproterenol, cocaine, and ionizing radiation.^[21]

Receptor activator of NF-κB (RANK), which is a type of TNFR, is a central activator of NF-κB. Osteoprotegerin (OPG), which is a decoy receptor homolog for RANK ligand (RANKL), inhibits RANK by binding to RANKL, and, thus, osteoprotegerin is tightly involved in regulating NF-κB activation.^[22]

Many bacterial products and stimulation of a wide variety of cell-surface receptors lead to NF-κB activation and fairly rapid changes in gene expression.^[1] The identification of Toll-like receptors (TLRs) as specific pattern recognition molecules and the finding that stimulation of TLRs leads to activation of NF-κB improved our understanding of how different pathogens activate NF-κB. For example, studies have identified TLR4 as the receptor for the LPS component of Gram-negative bacteria.^[23] TLRs are key regulators of both innate and adaptive immune responses.^[24]

Unlike RelA, RelB, and c-Rel, the p50 and p52 NF-κB subunits do not contain transactivation domains in their C terminal halves. Nevertheless, the p50 and p52 NF-κB members play critical roles in modulating the specificity of NF-κB function. Although homodimers of p50 and p52 are, in general, repressors of κB site transcription, both p50 and p52 participate in target gene transactivation by forming heterodimers with RelA, RelB, or c-Rel.^[25] In addition, p50 and p52 homodimers also bind to the nuclear protein Bcl-3, and such complexes can function as transcriptional activators.^[26]^[27]^[28]

Inhibition

In unstimulated cells, the NF-κB dimers are sequestered in the cytoplasm by a family of inhibitors, called IκBs (Inhibitor of κB), which are proteins that contain multiple copies of a sequence called ankyrin repeats. By virtue of their ankyrin repeat domains, the IκB proteins mask the nuclear localization signals (NLS) of NF-κB proteins and keep them sequestered in an inactive state in the cytoplasm.^[29]

Activation process (canonical/classical)

Activation of the NF-κB is initiated by the signal-induced degradation of IκB proteins. This occurs primarily via activation of a kinase called the IκB kinase (IKK). IKK is composed of a heterodimer of the catalytic IKKα and IKKβ subunits and a "master" regulatory protein termed NEMO (NF-κB essential modulator) or IKK gamma. When activated by signals, usually coming from the outside of the cell, the IκB kinase phosphorylates two serine residues located in an IκB regulatory domain. When phosphorylated on these serines (e.g., serines 32 and 36 in human IκBα), the IκB proteins are modified by a process called ubiquitination, which then leads them to be degraded by a cell structure called the proteasome.

With the degradation of IκB, the NF-κB complex is then freed to enter the nucleus where it can 'turn on' the expression of specific genes that have DNA-binding sites for NF-κB nearby. The activation of these genes by NF-κB then leads to the given physiological response, for example, an inflammatory or immune response, a cell survival response, or cellular proliferation. Translocation of NF-κB to nucleus can be detected immunocytochemically and measured by laser scanning cytometry.^[33] NF-κB turns on expression of its own repressor, IκBα. The newly synthesized IκBα then re-inhibits NF-κB and, thus, forms an auto feedback loop, which results in oscillating levels of NF-κB activity.^[34] In addition, several viruses, including the AIDS virus HIV, have binding sites for NF-κB that controls the expression of viral genes, which in turn contribute to viral replication or viral pathogenicity. In the case of HIV-1, activation of NF-κB may, at least in part, be involved in activation of the virus from a latent, inactive state.^[35] YopP is a factor secreted by Yersinia pestis, the causative agent of plague, that prevents the ubiquitination of IκB. This causes this pathogen to effectively inhibit the NF-κB pathway and thus block the immune response of a human infected with Yersinia.^[36]

Inhibitors of NF-κB activity

Concerning known protein inhibitors of NF-κB activity, one of them is IFRD1, which represses the activity of NF-κB p65 by enhancing the HDAC-mediated deacetylation of the p65 subunit at lysine 310, by favoring the recruitment of HDAC3 to p65. In fact IFRD1 forms trimolecular complexes with p65 and HDAC3.^[37]^[38]

The NAD{{+}}-dependent protein deacetylase and longevity factor SIRT1 inhibits NF-κB gene expression by deacetylating the RelA/p65 subunit of NF-kB at lysine 310.^[39]

Non-canonical/alternate pathway

A select set of cell-differentiating or developmental stimuli, such as lymphotoxin β-receptor (LTβR), BAFF or RANKL, activate the non-canonical NF-κB pathway to induce NF-κB/RelB:p52 dimer in the nucleus. In this pathway, activation of the NF-κB inducing kinase (NIK) upon receptor ligation led to the phosphorylation and subsequent proteasomal processing of the NF-κB2 precursor protein p100 into mature p52 subunit in an IKK1/IKKa dependent manner. Then p52 dimerizes with RelB to appear as a nuclear RelB:p52 DNA binding activity and regulate a distinct class of genes.^[40] In contrast to the canonical signaling that relies upon NEMO-IKK2 mediated degradation of IκBα, -β, -ε, the non-canonical signaling critically depends on NIK mediated processing of p100 into p52. Given their distinct regulations, these two pathways were thought to be independent of each other. However, recent analyses revealed that synthesis of the constituents of the non-canonical pathway, viz RelB and p52, is controlled by the canonical IKK2-IκB-RelA:p50 signaling.^[41] Moreover, generation of the canonical and non-canonical dimers, viz RelA:p50 and RelB:p52, within the cellular milieu are also mechanistically interlinked.^[41] These analyses suggest that an integrated NF-κB system network underlies activation of both RelA and RelB containing dimer and that a malfunctioning canonical pathway will lead to an aberrant cellular response also through the non-canonical pathway.

In immunity

NF-κB is a major transcription factor that regulates genes responsible for both the innate and adaptive immune response.^[42] Upon activation of either the T- or B-cell receptor, NF-κB becomes activated through distinct signaling components. Upon ligation of the T-cell receptor, protein kinase Lck is recruited and phosphorylates the ITAMs of the CD3 cytoplasmic tail. ZAP70 is then recruited to the phosphorylated ITAMs and helps recruit LAT and PLC-γ, which causes activation of PKC. Through a cascade of phosphorylation events, the kinase complex is activated and NF-κB is able to enter the nucleus to upregulate genes involved in T-cell development, maturation, and proliferation.^[43]

In the nervous system

In addition to roles in mediating cell survival, studies by Mark Mattson and others have shown that NF-κB has diverse functions in the nervous system including roles in plasticity, learning, and memory. In addition to stimuli that activate NF-κB in other tissues, NF-κB in the nervous system can be activated by Growth Factors (BDNF, NGF) and synaptic transmission such as glutamate.^[7] These activators of NF-κB in the nervous system all converge upon the IKK complex and the canonical pathway.

Recently there has been a great deal of interest in the role of NF-κB in the nervous system. Current studies suggest that NF-κB is important for learning and memory in multiple organisms including crabs,^[9]^[10] fruit flies,^[44] and mice.^[7]^[8] NF-κB may regulate learning and memory in part by modulating synaptic plasticity,^[6]^[61] synapse function,^[44]^[45]^[46] as well as by regulating the growth of dendrites^[47] and dendritic spines.^[46]

Genes that have NF-κB binding sites are shown to have increased expression following learning,^[8] suggesting that the transcriptional targets of NF-κB in the nervous system are important for plasticity. Many NF-κB target genes that may be important for plasticity and learning include growth factors (BDNF, NGF)^[48] cytokines (TNF-alpha, TNFR)^[49] and kinases (PKAc).^[50]

Despite the functional evidence for a role for Rel-family transcription factors in the nervous system, it is still not clear that the neurological effects of NF-κB reflect transcriptional activation in neurons. Most manipulations and assays are performed in the mixed-cell environments found in vivo, in "neuronal" cell cultures that contain significant numbers of glia, or in tumor-derived "neuronal" cell lines. When transfections or other manipulations have been targeted specifically at neurons, the endpoints measured are typically electrophysiology or other parameters far removed from gene transcription. Careful tests of NF-κB-dependent transcription in highly purified cultures of neurons generally show little to no NF-κB activity.^[51]^[52] Some of the reports of NF-κB in neurons appear to have been an artifact of antibody nonspecificity.^[53] Of course, artifacts of cell culture—e.g., removal of neurons from the influence of glia—could create spurious results as well. But this has been addressed in at least two coculture approaches. Moerman et al.^[54] used a coculture format whereby neurons and glia could be separated after treatment for EMSA analysis, and they found that the NF-κB induced by glutamatergic stimuli was restricted to glia (and, intriguingly, only glia that had been in the presence of neurons for 48 hours). The same investigators explored the issue in another approach, utilizing neurons from an NF-κB reporter transgenic mouse cultured with wild-type glia; glutamatergic stimuli again failed to activate in neurons.^[55] Some of the DNA-binding activity noted under certain conditions (particularly that reported as constitutive) appears to result from Sp3 and Sp4 binding to a subset of κB enhancer sequences in neurons.^[56] This activity is actually inhibited by glutamate and other conditions that elevate intraneuronal calcium. In the final analysis, the role of NF-κB in neurons remains opaque due to the difficulty of measuring transcription in cells that are simultaneously identified for type. Certainly, learning and memory could be influenced by transcriptional changes in astrocytes and other glial elements. And it should be considered that there could be mechanistic effects of NF-κB aside from direct transactivation of genes.

Clinical significance

Cancers

NF-κB is widely used by eukaryotic cells as a regulator of genes that control cell proliferation and cell survival. As such, many different types of human tumors have misregulated NF-κB: that is, NF-κB is constitutively active. Active NF-κB turns on the expression of genes that keep the cell proliferating and protect the cell from conditions that would otherwise cause it to die via apoptosis. In cancer, proteins that control NF-κB signaling are mutated or aberrantly expressed, leading to defective coordination between the malignant cell and the rest of the organism. This is evident both in metastasis, as well as in the inefficient eradication of the tumor by the immune system.^[57]

Normal cells can die when removed from the tissue they belong to, or when their genome cannot operate in harmony with tissue function: these events depend on feedback regulation of NF-κB, and fail in cancer.^[58]

Defects in NF-κB results in increased susceptibility to apoptosis leading to increased cell death. This is because NF-κB regulates anti-apoptotic genes especially the TRAF1 and TRAF2 and therefore abrogates the activities of the caspase family of enzymes, which are central to most apoptotic processes.^[59]

In tumor cells, NF-κB is active (for example, in 41% of Nasopharyngeal carcinoma^[60]) either due to mutations in genes encoding the NF-κB transcription factors themselves or in genes that control NF-κB activity (such as IκB genes); in addition, some tumor cells secrete factors that cause NF-κB to become active. Blocking NF-κB can cause tumor cells to stop proliferating, to die, or to become more sensitive to the action of anti-tumor agents. Thus, NF-κB is the subject of much active research among pharmaceutical companies as a target for anti-cancer therapy.^[61]

However, even though convincing experimental data have identified NF-κB as a critical promoter of tumorigenesis, which creates a solid rationale for the development of antitumor therapy that is based upon suppression of NF-κB activity, caution should be exercised when considering anti-NF-κB activity as a broad therapeutic strategy in cancer treatment as data has also shown that NF-κB activity enhances tumor cell sensitivity to apoptosis and senescence. In addition, it has been shown that canonical NF-κB is a Fas transcription activator and the alternative NF-κB is a Fas transcription repressor.^[62] Therefore, NF-κB promotes Fas-mediated apoptosis in cancer cells, and thus inhibition of NF-κB may suppress Fas-mediated apoptosis to impair host immune cell-mediated tumor suppression.

Inflammation

Because NF-κB controls many genes involved in inflammation, it is not surprising that NF-κB is found to be chronically active in many inflammatory diseases, such as inflammatory bowel disease, arthritis, sepsis, gastritis, asthma, atherosclerosis^[63] and others. It is important to note though, that elevation of some NF-κB activators, such as osteoprotegerin (OPG), are associated with elevated mortality, especially from cardiovascular diseases.^[64]^[65] Elevated NF-κB has also been associated with schizophrenia.^[66] Recently, NF-κB activation has been suggested as a possible molecular mechanism for the catabolic effects of cigarette smoke in skeletal muscle and sarcopenia.^[67]

Research has shown that during inflammation the function of a cell depends on signals it activates in response to contact with adjacent cells and to combinations of hormones, especially cytokines that act on it through specific receptors.^[68] A cells’ phenotype within a tissue develops through mutual stimulation of feedback signals that coordinate its function with other cells; this is especially evident during reprogramming of cell function when a tissue is exposed to inflammation, because cells alter their phenotype, and gradually express combinations of genes that prepare the tissue for regeneration after the cause of inflammation is removed.^[68]^[69] Particularly important are feedback responses that develop between tissue resident cells, and circulating cells of the immune system.^[69] Fidelity of feedback responses between diverse cell types and the immune system depends on the integrity of mechanisms that limit the range of genes activated by NF-κB, allowing only expression of genes which contribute to an effective immune response and subsequently, a complete restoration of tissue function after resolution of inflammation.^[69] In cancer, mechanisms that regulate gene expression in response to inflammatory stimuli are altered to the point that a cell ceases to link its survival with the mechanisms that coordinate its phenotype and its function with the rest of the tissue.^[58] This is often evident in severely compromised regulation of NF-κB activity, which allows cancer cells to express abnormal cohorts of NF-κB target genes.^[70] This results in not only the cancer cells functioning abnormally: cells of surrounding tissue alter their function and cease to support the organism exclusively. Additionally, several types of cells in the microenvironment of cancer may change their phenotypes to support cancer growth.^[71]^[72]^[73] Inflammation, therefore, is a process that tests the fidelity of tissue components because the process that leads to tissue regeneration requires coordination of gene expression between diverse cell types.^[68]^[74]

NEMO

Addiction

NF-κB is one of several induced transcriptional targets of ΔFosB which facilitates the development and maintenance of an addiction to a stimulus.^[76]^[77]^[78] In the caudate putamen, NF-κB induction is associated with increases in locomotion, whereas in the nucleus accumbens, NF-κB induction enhances the positive reinforcing effect of a drug through reward sensitization.^[77]

Non-drug inhibitors

Many natural products (including anti-oxidants) that have been promoted to have anti-cancer and anti-inflammatory activity have also been shown to inhibit NF-κB. There is a controversial US patent (US patent 6,410,516)^[80] that applies to the discovery and use of agents that can block NF-κB for therapeutic purposes. This patent is involved in several lawsuits, including Ariad v. Lilly. Recent work by Karin,^[81] Ben-Neriah^[82] and others has highlighted the importance of the connection between NF-κB, inflammation, and cancer, and underscored the value of therapies that regulate the activity of NF-κB.^[83]

Extracts from a number of herbs and dietary plants are efficient inhibitors of NF-κB activation in vitro.^[84]

The circumsporozoite protein of Plasmodium falciparum has been shown to be an inhibitor of NF-κB.^[85]

As a drug target

Aberrant activation of NF-κB is frequently observed in many cancers. Moreover, suppression of NF-κB limits the proliferation of cancer cells. In addition, NF-κB is a key player in the inflammatory response. Hence methods of inhibiting NF-κB signaling has potential therapeutic application in cancer and inflammatory diseases.^[86]^[87]

The discovery that activation of NF-κB nuclear translocation can be separated from the elevation of oxidant stress^[88] gives a promising avenue of development for strategies targeting NF-κB inhibition.

A new drug called denosumab acts to raise bone mineral density and reduce fracture rates in many patient sub-groups by inhibiting RANKL. RANKL acts through its receptor RANK, which in turn promotes NF-κB,^[89]

RANKL normally works by enabling the differentiation of osteoclasts from monocytes.

Anatabine's antiinflammatory effects are claimed to result from modulation of NF-κB activity.^[95] However the studies purporting its benefit use abnormally high doses in the millimolar range (similar to the extracellular potassium concentration), which are unlikely to be achieved in humans.

BAY 11-7082 has also been identified as a drug that can inhibit the NF-kB signaling cascade. It is capable of preventing the phosphorylation of IKK-α in an irreversible manner such that there is down regulation of NF-kB activation.^[96] In has been shown that administration of BAY 11-7082 rescued renal functionality in diabetic-induced Sprague-Dawley rats by suppressing NF-kB regulated oxidative stress.^[97]

The biological target of iguratimod, a drug marketed to treat rheumatoid arthritis in Japan and China, was unknown as of 2015, but the primary mechanism of action appeared to be preventing NF-κB activation.^[98]

See also

Notes

1. ^¹²³⁴{{cite journal | vauthors = Gilmore TD | title = Introduction to NF-kappaB: players, pathways, perspectives | journal = Oncogene | volume = 25 | issue = 51 | pages = 6680–4 | date = October 2006 | pmid = 17072321 | doi = 10.1038/sj.onc.1209954 }}
2. ^¹²{{cite journal | vauthors = Brasier AR | title = The NF-kappaB regulatory network | journal = Cardiovascular Toxicology | volume = 6 | issue = 2 | pages = 111–30 | year = 2006 | pmid = 17303919 | doi = 10.1385/CT:6:2:111 }}
3. ^¹²{{cite journal | vauthors = Perkins ND | title = Integrating cell-signalling pathways with NF-kappaB and IKK function | journal = Nature Reviews Molecular Cell Biology | volume = 8 | issue = 1 | pages = 49–62 | date = January 2007 | pmid = 17183360 | doi = 10.1038/nrm2083 }}
4. ^{{cite journal | vauthors = Gilmore TD | title = The Rel/NF-kappaB signal transduction pathway: introduction | journal = Oncogene | volume = 18 | issue = 49 | pages = 6842–4 | date = November 1999 | pmid = 10602459 | doi = 10.1038/sj.onc.1203237 }}
5. ^{{cite journal | vauthors = Tian B, Brasier AR | title = Identification of a nuclear factor kappa B-dependent gene network | journal = Recent Progress in Hormone Research | volume = 58 | issue = | pages = 95–130 | year = 2003 | pmid = 12795416 | doi = 10.1210/rp.58.1.95 }}
6. ^¹{{cite journal | vauthors = Albensi BC, Mattson MP | title = Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity | journal = Synapse | volume = 35 | issue = 2 | pages = 151–9 | date = February 2000 | pmid = 10611641 | doi = 10.1002/(SICI)1098-2396(200002)35:2<151::AID-SYN8>3.0.CO;2-P }}
7. ^¹²{{cite journal | vauthors = Meffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D | title = NF-kappa B functions in synaptic signaling and behavior | journal = Nature Neuroscience | volume = 6 | issue = 10 | pages = 1072–8 | date = October 2003 | pmid = 12947408 | doi = 10.1038/nn1110 }}
8. ^¹²{{cite journal | vauthors = Levenson JM, Choi S, Lee SY, Cao YA, Ahn HJ, Worley KC, Pizzi M, Liou HC, Sweatt JD | title = A bioinformatics analysis of memory consolidation reveals involvement of the transcription factor c-rel | journal = The Journal of Neuroscience | volume = 24 | issue = 16 | pages = 3933–43 | date = April 2004 | pmid = 15102909 | doi = 10.1523/JNEUROSCI.5646-03.2004 }}
9. ^¹{{cite journal | vauthors = Freudenthal R, Locatelli F, Hermitte G, Maldonado H, Lafourcade C, Delorenzi A, Romano A | title = Kappa-B like DNA-binding activity is enhanced after spaced training that induces long-term memory in the crab Chasmagnathus | journal = Neuroscience Letters | volume = 242 | issue = 3 | pages = 143–6 | date = February 1998 | pmid = 9530926 | doi = 10.1016/S0304-3940(98)00059-7 }}
10. ^¹{{cite journal | vauthors = Merlo E, Freudenthal R, Romano A | title = The IkappaB kinase inhibitor sulfasalazine impairs long-term memory in the crab Chasmagnathus | journal = Neuroscience | volume = 112 | issue = 1 | pages = 161–72 | year = 2002 | pmid = 12044481 | doi = 10.1016/S0306-4522(02)00049-0 }}
11. ^{{cite journal | vauthors = Park HJ, Youn HS | title = Mercury induces the expression of cyclooxygenase-2 and inducible nitric oxide synthase | journal = Toxicology and Industrial Health | volume = 29 | issue = 2 | pages = 169–74 | date = March 2013 | pmid = 22080037 | doi = 10.1177/0748233711427048 }}
12. ^{{cite journal | vauthors = Sen R, Baltimore D | title = Multiple nuclear factors interact with the immunoglobulin enhancer sequences | journal = Cell | volume = 46 | issue = 5 | pages = 705–16 | date = August 1986 | pmid = 3091258 | doi = 10.1016/0092-8674(86)90346-6 }}
13. ^{{cite journal | vauthors = Karin M, Ben-Neriah Y | title = Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity | journal = Annual Review of Immunology | volume = 18 | issue = | pages = 621–63 | year = 2000 | pmid = 10837071 | doi = 10.1146/annurev.immunol.18.1.621 }}
14. ^{{cite journal | vauthors = Senftleben U, Cao Y, Xiao G, Greten FR, Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M | title = Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway | journal = Science | volume = 293 | issue = 5534 | pages = 1495–9 | date = August 2001 | pmid = 11520989 | doi = 10.1126/science.1062677 }}
15. ^{{cite journal | vauthors = Plaksin D, Baeuerle PA, Eisenbach L | title = KBF1 (p50 NF-kappa B homodimer) acts as a repressor of H-2Kb gene expression in metastatic tumor cells | journal = The Journal of Experimental Medicine | volume = 177 | issue = 6 | pages = 1651–62 | date = June 1993 | pmid = 8496683 | doi = 10.1084/jem.177.6.1651 | pmc=2191052}}
16. ^{{cite journal | vauthors = Guan H, Hou S, Ricciardi RP | title = DNA binding of repressor nuclear factor-kappaB p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit | journal = The Journal of Biological Chemistry | volume = 280 | issue = 11 | pages = 9957–62 | date = March 2005 | pmid = 15642694 | doi = 10.1074/jbc.m412180200 }}
17. ^{{cite journal | vauthors = Nabel GJ, Verma IM | title = Proposed NF-kappa B/I kappa B family nomenclature | journal = Genes & Development | volume = 7 | issue = 11 | pages = 2063 | date = November 1993 | pmid = 8224837 | doi = 10.1101/gad.7.11.2063 }}
18. ^{{cite journal | vauthors = Ghosh S, May MJ, Kopp EB | title = NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses | journal = Annual Review of Immunology | volume = 16 | issue = | pages = 225–60 | year = 1998 | pmid = 9597130 | doi = 10.1146/annurev.immunol.16.1.225 }}
19. ^{{cite journal | vauthors = Waterhouse RM, Kriventseva EV, Meister S, Xi Z, Alvarez KS, Bartholomay LC, Barillas-Mury C, Bian G, Blandin S, Christensen BM, Dong Y, Jiang H, Kanost MR, Koutsos AC, Levashina EA, Li J, Ligoxygakis P, Maccallum RM, Mayhew GF, Mendes A, Michel K, Osta MA, Paskewitz S, Shin SW, Vlachou D, Wang L, Wei W, Zheng L, Zou Z, Severson DW, Raikhel AS, Kafatos FC, Dimopoulos G, Zdobnov EM, Christophides GK | title = Evolutionary dynamics of immune-related genes and pathways in disease-vector mosquitoes | journal = Science | volume = 316 | issue = 5832 | pages = 1738–43 | date = June 2007 | pmid = 17588928 | pmc = 2042107 | doi = 10.1126/science.1139862 }}
20. ^{{PDB|3do7}}; {{cite journal | vauthors = Fusco AJ, Huang DB, Miller D, Wang VY, Vu D, Ghosh G | title = NF-kappaB p52:RelB heterodimer recognizes two classes of kappaB sites with two distinct modes | journal = EMBO Reports | volume = 10 | issue = 2 | pages = 152–9 | date = February 2009 | pmid = 19098713 | pmc = 2637311 | doi = 10.1038/embor.2008.227 }}
21. ^(a) {{cite journal | vauthors = Chandel NS, Trzyna WC, McClintock DS, Schumacker PT | title = Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin | journal = Journal of Immunology | volume = 165 | issue = 2 | pages = 1013–21 | date = July 2000 | pmid = 10878378 | doi = 10.4049/jimmunol.165.2.1013 }}; (b) {{cite journal | vauthors = Fitzgerald DC, Meade KG, McEvoy AN, Lillis L, Murphy EP, MacHugh DE, Baird AW | title = Tumour necrosis factor-alpha (TNF-alpha) increases nuclear factor kappaB (NFkappaB) activity in and interleukin-8 (IL-8) release from bovine mammary epithelial cells | journal = Veterinary Immunology and Immunopathology | volume = 116 | issue = 1–2 | pages = 59–68 | date = March 2007 | pmid = 17276517 | doi = 10.1016/j.vetimm.2006.12.008 }}; (c) {{cite journal | vauthors = Renard P, Zachary MD, Bougelet C, Mirault ME, Haegeman G, Remacle J, Raes M | title = Effects of antioxidant enzyme modulations on interleukin-1-induced nuclear factor kappa B activation | journal = Biochemical Pharmacology | volume = 53 | issue = 2 | pages = 149–60 | date = January 1997 | pmid = 9037247 | doi = 10.1016/S0006-2952(96)00645-4 }}; (d) {{cite journal | vauthors = Qin H, Wilson CA, Lee SJ, Zhao X, Benveniste EN | title = LPS induces CD40 gene expression through the activation of NF-kappaB and STAT-1alpha in macrophages and microglia | journal = Blood | volume = 106 | issue = 9 | pages = 3114–22 | date = November 2005 | pmid = 16020513 | pmc = 1895321 | doi = 10.1182/blood-2005-02-0759 }}; (e) {{cite journal | vauthors = Takemoto Y, Yoshiyama M, Takeuchi K, Omura T, Komatsu R, Izumi Y, Kim S, Yoshikawa J | title = Increased JNK, AP-1 and NF-kappa B DNA binding activities in isoproterenol-induced cardiac remodeling | journal = Journal of Molecular and Cellular Cardiology | volume = 31 | issue = 11 | pages = 2017–30 | date = November 1999 | pmid = 10591028 | doi = 10.1006/jmcc.1999.1033 }}; (f) {{cite journal | vauthors = Hargrave BY, Tiangco DA, Lattanzio FA, Beebe SJ | title = Cocaine, not morphine, causes the generation of reactive oxygen species and activation of NF-kappaB in transiently cotransfected heart cells | journal = Cardiovascular Toxicology | volume = 3 | issue = 2 | pages = 141–51 | year = 2003 | pmid = 14501032 | doi = 10.1385/CT:3:2:141 }}; (g) {{cite journal | vauthors = Basu S, Rosenzweig KR, Youmell M, Price BD | title = The DNA-dependent protein kinase participates in the activation of NF kappa B following DNA damage | journal = Biochemical and Biophysical Research Communications | volume = 247 | issue = 1 | pages = 79–83 | date = June 1998 | pmid = 9636658 | doi = 10.1006/bbrc.1998.8741 }}
22. ^{{cite journal | vauthors = Baud'huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D | title = RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases | journal = Cellular and Molecular Life Sciences | volume = 64 | issue = 18 | pages = 2334–50 | date = September 2007 | pmid = 17530461 | doi = 10.1007/s00018-007-7104-0 }}
23. ^{{cite journal | vauthors = Doyle SL, O'Neill LA | title = Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity | journal = Biochemical Pharmacology | volume = 72 | issue = 9 | pages = 1102–13 | date = October 2006 | pmid = 16930560 | doi = 10.1016/j.bcp.2006.07.010 }}
24. ^{{cite journal | vauthors = Hayden MS, West AP, Ghosh S | title = NF-kappaB and the immune response | journal = Oncogene | volume = 25 | issue = 51 | pages = 6758–80 | date = October 2006 | pmid = 17072327 | doi = 10.1038/sj.onc.1209943 }}
25. ^{{cite journal | vauthors = Li Q, Verma IM | title = NF-kappaB regulation in the immune system | journal = Nature Reviews. Immunology | volume = 2 | issue = 10 | pages = 725–34 | date = October 2002 | pmid = 12360211 | doi = 10.1038/nri910 }}
26. ^{{cite journal | vauthors = Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D | title = The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers | journal = Genes & Development | volume = 7 | issue = 7B | pages = 1354–63 | date = July 1993 | pmid = 8330739 | doi = 10.1101/gad.7.7b.1354 }}
27. ^{{cite journal | vauthors = Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U | title = The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition | journal = Nature | volume = 359 | issue = 6393 | pages = 339–42 | date = September 1992 | pmid = 1406939 | doi = 10.1038/359339a0 }}
28. ^{{cite journal | vauthors = Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U | title = The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers | journal = Cell | volume = 72 | issue = 5 | pages = 729–39 | date = March 1993 | pmid = 8453667 | doi = 10.1016/0092-8674(93)90401-B }}
29. ^{{cite journal | vauthors = Jacobs MD, Harrison SC | title = Structure of an IkappaBalpha/NF-kappaB complex | journal = Cell | volume = 95 | issue = 6 | pages = 749–58 | date = December 1998 | pmid = 9865693 | doi = 10.1016/S0092-8674(00)81698-0 }}
30. ^¹{{cite journal | vauthors = Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, Hoffmann A | title = A fourth IkappaB protein within the NF-kappaB signaling module | journal = Cell | volume = 128 | issue = 2 | pages = 369–81 | date = January 2007 | pmid = 17254973 | pmc = 1831796 | doi = 10.1016/j.cell.2006.12.033 }}.
31. ^{{cite journal | vauthors = Dobrzanski P, Ryseck RP, Bravo R | title = Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100 | journal = Oncogene | volume = 10 | issue = 5 | pages = 1003–7 | date = March 1995 | pmid = 7898917 | doi = }}
32. ^{{cite journal | vauthors = Lo JC, Basak S, James ES, Quiambo RS, Kinsella MC, Alegre ML, Weih F, Franzoso G, Hoffmann A, Fu YX | title = Coordination between NF-kappaB family members p50 and p52 is essential for mediating LTbetaR signals in the development and organization of secondary lymphoid tissues | journal = Blood | volume = 107 | issue = 3 | pages = 1048–55 | date = February 2006 | pmid = 16195333 | pmc = 1895903 | doi = 10.1182/blood-2005-06-2452 }}
33. ^{{cite journal | vauthors = Deptala A, Bedner E, Gorczyca W, Darzynkiewicz Z | title = Activation of nuclear factor kappa B (NF-kappaB) assayed by laser scanning cytometry (LSC) | journal = Cytometry | volume = 33 | issue = 3 | pages = 376–82 | date = November 1998 | pmid = 9822350 | pmc = 3874872 | doi = }}
34. ^{{cite journal | vauthors = Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE, Nelson G, See V, Horton CA, Spiller DG, Edwards SW, McDowell HP, Unitt JF, Sullivan E, Grimley R, Benson N, Broomhead D, Kell DB, White MR | title = Oscillations in NF-kappaB signaling control the dynamics of gene expression | journal = Science | volume = 306 | issue = 5696 | pages = 704–8 | date = October 2004 | pmid = 15499023 | doi = 10.1126/science.1099962 }}
35. ^{{cite journal | vauthors = Hiscott J, Kwon H, Génin P | title = Hostile takeovers: viral appropriation of the NF-kappaB pathway | journal = The Journal of Clinical Investigation | volume = 107 | issue = 2 | pages = 143–51 | date = January 2001 | pmid = 11160127 | pmc = 199181 | doi = 10.1172/JCI11918 }}
36. ^{{cite journal | vauthors = Adkins I, Schulz S, Borgmann S, Autenrieth IB, Gröbner S | title = Differential roles of Yersinia outer protein P-mediated inhibition of nuclear factor-kappa B in the induction of cell death in dendritic cells and macrophages | journal = Journal of Medical Microbiology | volume = 57 | issue = Pt 2 | pages = 139–44 | date = February 2008 | pmid = 18201977 | doi = 10.1099/jmm.0.47437-0 }}
37. ^{{cite journal | vauthors = Micheli L, Leonardi L, Conti F, Buanne P, Canu N, Caruso M, Tirone F | title = PC4 coactivates MyoD by relieving the histone deacetylase 4-mediated inhibition of myocyte enhancer factor 2C | journal = Molecular and Cellular Biology | volume = 25 | issue = 6 | pages = 2242–59 | date = March 2005 | pmid = 15743821 | pmc = 1061592 | doi = 10.1128/MCB.25.6.2242-2259.2005 }}
38. ^{{cite journal | vauthors = Micheli L, Leonardi L, Conti F, Maresca G, Colazingari S, Mattei E, Lira SA, Farioli-Vecchioli S, Caruso M, Tirone F | title = PC4/Tis7/IFRD1 stimulates skeletal muscle regeneration and is involved in myoblast differentiation as a regulator of MyoD and NF-kappaB | journal = The Journal of Biological Chemistry | volume = 286 | issue = 7 | pages = 5691–707 | date = February 2011 | pmid = 21127072 | pmc = 3037682 | doi = 10.1074/jbc.M110.162842 }}
39. ^{{cite journal | vauthors = Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW | title = Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase | journal = The EMBO Journal | volume = 23 | issue = 12 | pages = 2369–80 | date = June 2004 | pmid = 15152190 | doi = 10.1038/sj.emboj.7600244 | pmc=423286}}
40. ^{{cite journal | vauthors = Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, Vu D, Jegga AG, Aronow BJ, Ghosh G, Rickert RC, Karin M | title = Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers | journal = The EMBO Journal | volume = 23 | issue = 21 | pages = 4202–10 | date = October 2004 | pmid = 15470505 | pmc = 524385 | doi = 10.1038/sj.emboj.7600391 }}
41. ^¹{{cite journal | vauthors = Basak S, Shih VF, Hoffmann A | title = Generation and activation of multiple dimeric transcription factors within the NF-kappaB signaling system | journal = Molecular and Cellular Biology | volume = 28 | issue = 10 | pages = 3139–50 | date = May 2008 | pmid = 18299388 | pmc = 2423155 | doi = 10.1128/MCB.01469-07 }}
42. ^{{cite journal | vauthors = Smith EM, Gregg M, Hashemi F, Schott L, Hughes TK | title = Corticotropin Releasing Factor (CRF) activation of NF-kappaB-directed transcription in leukocytes | journal = Cellular and Molecular Neurobiology | volume = 26 | issue = 4–6 | pages = 1021–36 | date = 2006-07-01 | pmid = 16633893 | doi = 10.1007/s10571-006-9040-1 }}
43. ^{{cite journal | vauthors = Livolsi A, Busuttil V, Imbert V, Abraham RT, Peyron JF | title = Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases | journal = European Journal of Biochemistry | volume = 268 | issue = 5 | pages = 1508–15 | date = March 2001 | pmid = 11231305 | doi = 10.1046/j.1432-1327.2001.02028.x }}
44. ^¹{{cite journal | vauthors = Heckscher ES, Fetter RD, Marek KW, Albin SD, Davis GW | title = NF-kappaB, IkappaB, and IRAK control glutamate receptor density at the Drosophila NMJ | journal = Neuron | volume = 55 | issue = 6 | pages = 859–73 | date = September 2007 | pmid = 17880891 | pmc = 2701504 | doi = 10.1016/j.neuron.2007.08.005 }}
45. ^{{cite journal | vauthors = Wang J, Fu XQ, Lei WL, Wang T, Sheng AL, Luo ZG | title = Nuclear factor kappaB controls acetylcholine receptor clustering at the neuromuscular junction | journal = The Journal of Neuroscience | volume = 30 | issue = 33 | pages = 11104–13 | date = August 2010 | pmid = 20720118 | doi = 10.1523/JNEUROSCI.2118-10.2010 }}
46. ^¹{{cite journal | vauthors = Boersma MC, Dresselhaus EC, De Biase LM, Mihalas AB, Bergles DE, Meffert MK | title = A requirement for nuclear factor-kappaB in developmental and plasticity-associated synaptogenesis | journal = The Journal of Neuroscience | volume = 31 | issue = 14 | pages = 5414–25 | date = April 2011 | pmid = 21471377 | pmc = 3113725 | doi = 10.1523/JNEUROSCI.2456-10.2011 }}
47. ^{{cite journal | vauthors = Gutierrez H, Hale VA, Dolcet X, Davies A | title = NF-kappaB signalling regulates the growth of neural processes in the developing PNS and CNS | journal = Development | volume = 132 | issue = 7 | pages = 1713–26 | date = April 2005 | pmid = 15743881 | doi = 10.1242/dev.01702 }}
48. ^{{cite journal | vauthors = Zaheer A, Yorek MA, Lim R | title = Effects of glia maturation factor overexpression in primary astrocytes on MAP kinase activation, transcription factor activation, and neurotrophin secretion | journal = Neurochemical Research | volume = 26 | issue = 12 | pages = 1293–9 | date = December 2001 | pmid = 11885780 | doi = 10.1023/A:1014241300179 }}
49. ^{{cite journal | vauthors = Qiu J, Hu X, Nesic O, Grafe MR, Rassin DK, Wood TG, Perez-Polo JR | title = Effects of NF-kappaB oligonucleotide "decoys" on gene expression in P7 rat hippocampus after hypoxia/ischemia | journal = Journal of Neuroscience Research | volume = 77 | issue = 1 | pages = 108–18 | date = July 2004 | pmid = 15197744 | doi = 10.1002/jnr.20156 }}
50. ^¹{{cite journal | vauthors = Kaltschmidt B, Ndiaye D, Korte M, Pothion S, Arbibe L, Prüllage M, Pfeiffer J, Lindecke A, Staiger V, Israël A, Kaltschmidt C, Mémet S | title = NF-kappaB regulates spatial memory formation and synaptic plasticity through protein kinase A/CREB signaling | journal = Molecular and Cellular Biology | volume = 26 | issue = 8 | pages = 2936–46 | date = April 2006 | pmid = 16581769 | pmc = 1446931 | doi = 10.1128/MCB.26.8.2936-2946.2006 }}
51. ^{{cite journal | vauthors = Listwak SJ, Rathore P, Herkenham M | title = Minimal NF-κB activity in neurons | journal = Neuroscience | volume = 250 | pages = 282–99 | date = October 2013 | pmid = 23872390 | doi = 10.1016/j.neuroscience.2013.07.013 | pmc=3785079}}
52. ^{{cite journal | vauthors = Jarosinski KW, Whitney LW, Massa PT | title = Specific deficiency in nuclear factor-kappaB activation in neurons of the central nervous system | journal = Laboratory Investigation; A Journal of Technical Methods and Pathology | volume = 81 | issue = 9 | pages = 1275–88 | date = September 2001 | pmid = 11555675 | doi = 10.1038/labinvest.3780341 }}
53. ^{{cite journal | vauthors = Herkenham M, Rathore P, Brown P, Listwak SJ | title = Cautionary notes on the use of NF-κB p65 and p50 antibodies for CNS studies | journal = Journal of Neuroinflammation | volume = 8 | pages = 141 | date = October 2011 | pmid = 21999414 | doi = 10.1186/1742-2094-8-141 | pmc=3210105}}
54. ^{{cite journal | vauthors = Moerman AM, Mao X, Lucas MM, Barger SW | title = Characterization of a neuronal kappaB-binding factor distinct from NF-kappaB | journal = Brain Research. Molecular Brain Research | volume = 67 | issue = 2 | pages = 303–15 | date = April 1999 | pmid = 10216229 | doi = 10.1016/s0169-328x(99)00091-1 }}
55. ^{{cite journal | vauthors = Mao XR, Moerman-Herzog AM, Chen Y, Barger SW | title = Unique aspects of transcriptional regulation in neurons--nuances in NFkappaB and Sp1-related factors | journal = Journal of Neuroinflammation | volume = 6 | pages = 16 | date = May 2009 | pmid = 19450264 | doi = 10.1186/1742-2094-6-16 | pmc=2693111}}
56. ^{{cite journal | vauthors = Mao X, Yang SH, Simpkins JW, Barger SW | title = Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons | journal = Journal of Neurochemistry | volume = 100 | issue = 5 | pages = 1300–14 | date = March 2007 | pmid = 17316402 | doi = 10.1111/j.1471-4159.2006.04297.x | pmc=1949346}}
57. ^{{cite journal | last1 = Vlahopoulos | first1 = SA | title = Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode. | journal = Cancer biology & medicine | date = August 2017 | pmid = 28884042 | doi = 10.20892/j.issn.2095-3941.2017.0029 | volume = 14 | pages = 254–270 | pmc = 5570602}}
58. ^¹{{cite journal | vauthors = Vlahopoulos SA, Cen O, Hengen N, Agan J, Moschovi M, Critselis E, Adamaki M, Bacopoulou F, Copland JA, Boldogh I, Karin M, Chrousos GP | title = Dynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironment | journal = Cytokine & Growth Factor Reviews | volume = 26 | issue = 4 | pages = 389–403 | date = August 2015 | pmid = 26119834 | doi = 10.1016/j.cytogfr.2015.06.001 | pmc=4526340}}
59. ^{{cite journal | vauthors = Sheikh MS, Huang Y | title = Death receptor activation complexes: it takes two to activate TNF receptor 1 | journal = Cell Cycle | volume = 2 | issue = 6 | pages = 550–2 | year = 2003 | pmid = 14504472 | doi = 10.4161/cc.2.6.566 | url = http://www.landesbioscience.com/journals/cc/article/566/ }}
60. ^{{cite journal | vauthors = Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, Woo JK, Yip KY, Seo J, Hui EP, Mak MK, Rusan M, Chau NG, Or YY, Law MH, Law PP, Liu ZW, Ngan HL, Hau PM, Verhoeft KR, Poon PH, Yoo SK, Shin JY, Lee SD, Lun SW, Jia L, Chan AW, Chan JY, Lai PB, Fung CY, Hung ST, Wang L, Chang AM, Chiosea SI, Hedberg ML, Tsao SW, van Hasselt AC, Chan AT, Grandis JR, Hammerman PS, Lo KW | display-authors = 6 | title = Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations | journal = Nature Communications | volume = 8 | pages = 14121 | date = January 2017 | pmid = 28098136 | doi = 10.1038/ncomms14121 | pmc=5253631}}
61. ^{{cite journal | vauthors = Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A | title = The transcription factor nuclear factor-kappa B and cancer | journal = Clinical Oncology | volume = 19 | issue = 2 | pages = 154–61 | date = March 2007 | pmid = 17355113 | doi = 10.1016/j.clon.2006.11.013 }}
62. ^{{cite journal | vauthors = Liu F, Bardhan K, Yang D, Thangaraju M, Ganapathy V, Waller JL, Liles GB, Lee JR, Liu K | title = NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression | journal = The Journal of Biological Chemistry | volume = 287 | issue = 30 | pages = 25530–40 | date = July 2012 | pmid = 22669972 | doi = 10.1074/jbc.M112.356279 | pmc = 3408167 }}
63. ^{{cite journal | vauthors = Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M | title = Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 101 | issue = 15 | pages = 5634–9 | date = April 2004 | pmid = 15064395 | pmc = 397455 | doi = 10.1073/pnas.0401060101 }}
64. ^{{cite journal | vauthors = Venuraju SM, Yerramasu A, Corder R, Lahiri A | title = Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity | journal = Journal of the American College of Cardiology | volume = 55 | issue = 19 | pages = 2049–61 | date = May 2010 | pmid = 20447527 | doi = 10.1016/j.jacc.2010.03.013 }}
65. ^{{cite journal | vauthors = Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF, Rong J, Corey D, Hoffmann U, Fox CS, Vasan RS, Benjamin EJ, O'Donnell CJ, Kathiresan S | title = Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality | journal = Arteriosclerosis, Thrombosis, and Vascular Biology | volume = 30 | issue = 9 | pages = 1849–54 | date = September 2010 | pmid = 20448212 | pmc = 3039214 | doi = 10.1161/ATVBAHA.109.199661 }}
66. ^{{cite journal | vauthors = Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP | title = The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia | journal = Biological Psychiatry | volume = 65 | issue = 6 | pages = 481–8 | date = March 2009 | pmid = 19058794 | doi = 10.1016/j.biopsych.2008.10.018 }}
67. ^{{cite journal | vauthors = Kaisari S, Rom O, Aizenbud D, Reznick AZ | title = Involvement of NF-κB and muscle specific E3 ubiquitin ligase MuRF1 in cigarette smoke-induced catabolism in C2 myotubes | journal = Advances in Experimental Medicine and Biology | volume = 788 | issue = | pages = 7–17 | year = 2013 | pmid = 23835952 | doi = 10.1007/978-94-007-6627-3_2 }}
68. ^¹²{{cite journal | vauthors = Hajishengallis G, Chavakis T | title = Endogenous modulators of inflammatory cell recruitment | journal = Trends in Immunology | volume = 34 | issue = 1 | pages = 1–6 | date = January 2013 | pmid = 22951309 | doi = 10.1016/j.it.2012.08.003 | pmc=3703146}}
69. ^¹²{{cite journal | vauthors = Vidal PM, Lemmens E, Dooley D, Hendrix S | title = The role of "anti-inflammatory" cytokines in axon regeneration | journal = Cytokine & Growth Factor Reviews | volume = 24 | issue = 1 | pages = 1–12 | date = February 2013 | pmid = 22985997 | doi = 10.1016/j.cytogfr.2012.08.008 }}
70. ^{{cite journal | vauthors = Grivennikov SI, Karin M | title = Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer | journal = Cytokine & Growth Factor Reviews | volume = 21 | issue = 1 | pages = 11–9 | date = February 2010 | pmid = 20018552 | doi = 10.1016/j.cytogfr.2009.11.005 | pmc=2834864}}
71. ^{{cite journal | vauthors = Bonavita E, Galdiero MR, Jaillon S, Mantovani A | title = Phagocytes as Corrupted Policemen in Cancer-Related Inflammation | journal = Advances in Cancer Research | volume = 128 | pages = 141–71 | year = 2015 | pmid = 26216632 | doi = 10.1016/bs.acr.2015.04.013 }}
72. ^{{cite journal | vauthors = Sionov RV, Fridlender ZG, Granot Z | title = The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment | journal = Cancer Microenvironment | volume = 8 | issue = 3 | pages = 125–58 | date = December 2015 | pmid = 24895166 | doi = 10.1007/s12307-014-0147-5 | pmc=4714999}}
73. ^{{cite journal | vauthors = Kong X, Li L, Li Z, Xie K | title = Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications | journal = Cytokine & Growth Factor Reviews | volume = 23 | issue = 6 | pages = 343–56 | date = December 2012 | pmid = 22749856 | doi = 10.1016/j.cytogfr.2012.06.006 | pmc=3505269}}
74. ^{{cite journal | vauthors = Mecollari V, Nieuwenhuis B, Verhaagen J | title = A perspective on the role of class III semaphorin signaling in central nervous system trauma | journal = Frontiers in Cellular Neuroscience | volume = 8 | pages = 328 | year = 2014 | pmid = 25386118 | pmc = 4209881 | doi = 10.3389/fncel.2014.00328 }}
75. ^NEMO deficiency syndrome information, Great Ormond Street Hospital for Children
76. ^{{cite journal | vauthors = Robison AJ, Nestler EJ | title = Transcriptional and epigenetic mechanisms of addiction | journal = Nature Reviews. Neuroscience | volume = 12 | issue = 11 | pages = 623–37 | date = October 2011 | pmid = 21989194 | pmc = 3272277 | doi = 10.1038/nrn3111 }}
77. ^¹²³{{cite journal | vauthors = Ruffle JK | title = Molecular neurobiology of addiction: what's all the (Δ)FosB about? | journal = The American Journal of Drug and Alcohol Abuse | volume = 40 | issue = 6 | pages = 428–37 | date = November 2014 | pmid = 25083822 | doi = 10.3109/00952990.2014.933840 | quote = }}
78. ^¹{{cite journal | vauthors = Nestler EJ | title = Cellular basis of memory for addiction | journal = Dialogues in Clinical Neuroscience | volume = 15 | issue = 4 | pages = 431–43 | date = December 2013 | pmid = 24459410 | pmc = 3898681 | doi = | quote = }}
79. ^¹{{cite journal | vauthors = Nestler EJ | title = Review. Transcriptional mechanisms of addiction: role of DeltaFosB | journal = Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences | volume = 363 | issue = 1507 | pages = 3245–55 | date = October 2008 | pmid = 18640924 | pmc = 2607320 | doi = 10.1098/rstb.2008.0067 | quote = }}
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607320/table/tbl3/ Table 3]
80. ^{{US patent reference | number = 6410516 | y = 2002 | m = 06 | d = 25 | inventor = Baltimore D; Sen R; Sharp PA; Singh H; Staudt L; Lebowitz JH; Baldwin Jr AS; Clerc RG; Corcoran LM; Baeuerle PA; Lenardo MJ; Fan C-M; Maniatis TPD | title = Nuclear factors associated with transcriptional regulation}}
81. ^{{cite journal | vauthors = Karin M | title = The IkappaB kinase - a bridge between inflammation and cancer | journal = Cell Research | volume = 18 | issue = 3 | pages = 334–42 | date = March 2008 | pmid = 18301380 | doi = 10.1038/cr.2008.30 }}
82. ^{{cite journal | vauthors = Pikarsky E, Ben-Neriah Y | title = NF-kappaB inhibition: a double-edged sword in cancer? | journal = European Journal of Cancer | volume = 42 | issue = 6 | pages = 779–84 | date = April 2006 | pmid = 16530406 | doi = 10.1016/j.ejca.2006.01.011 }}
83. ^{{cite journal | vauthors = Mantovani A, Marchesi F, Portal C, Allavena P, Sica A | title = Linking inflammation reactions to cancer: novel targets for therapeutic strategies | journal = Advances in Experimental Medicine and Biology | volume = 610 | issue = | pages = 112–27 | year = 2008 | pmid = 18593019 | doi = 10.1007/978-0-387-73898-7_9 }}
84. ^{{cite journal | vauthors = Paur I, Balstad TR, Kolberg M, Pedersen MK, Austenaa LM, Jacobs DR, Blomhoff R | title = Extract of oregano, coffee, thyme, clove, and walnuts inhibits NF-kappaB in monocytes and in transgenic reporter mice | journal = Cancer Prevention Research | volume = 3 | issue = 5 | pages = 653–63 | date = May 2010 | pmid = 20424131 | doi = 10.1158/1940-6207.CAPR-09-0089 }}
85. ^{{cite journal | vauthors = Ding Y, Huang X, Liu T, Fu Y, Tan Z, Zheng H, Zhou T, Dai J, Xu W | title = The Plasmodium circumsporozoite protein, a novel NF-κB inhibitor, suppresses the growth of SW480 | journal = Pathology Oncology Research | volume = 18 | issue = 4 | pages = 895–902 | date = October 2012 | pmid = 22678765 | doi = 10.1007/s12253-012-9519-7 }}
86. ^{{cite journal | vauthors = Garg A, Aggarwal BB | title = Nuclear transcription factor-kappaB as a target for cancer drug development | journal = Leukemia | volume = 16 | issue = 6 | pages = 1053–68 | date = June 2002 | pmid = 12040437 | doi = 10.1038/sj.leu.2402482 }}
87. ^{{cite journal | vauthors = Sethi G, Sung B, Aggarwal BB | title = Nuclear factor-kappaB activation: from bench to bedside | journal = Experimental Biology and Medicine | volume = 233 | issue = 1 | pages = 21–31 | date = January 2008 | pmid = 18156302 | doi = 10.3181/0707-MR-196 }}
88. ^{{cite journal | vauthors = Vlahopoulos S, Boldogh I, Casola A, Brasier AR | title = Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation | journal = Blood | volume = 94 | issue = 6 | pages = 1878–89 | date = September 1999 | pmid = 10477716 | doi = | url = http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;94/6/1878 }}
89. ^{{cite journal | vauthors = Hamdy NA | title = Denosumab: RANKL inhibition in the management of bone loss | journal = Drugs of Today | volume = 44 | issue = 1 | pages = 7–21 | date = January 2008 | pmid = 18301800 | doi = 10.1358/dot.2008.44.1.1178467 }}
90. ^{{cite journal | vauthors = Cvek B, Dvorak Z | title = Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals | journal = Current Pharmaceutical Design | volume = 13 | issue = 30 | pages = 3155–67 | year = 2007 | pmid = 17979756 | doi = 10.2174/138161207782110390 }}
91. ^{{cite journal | vauthors = Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG | title = NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer | journal = Cell Reports | volume = 11 | issue = 1 | pages = 98–110 | date = April 2015 | pmid = 25843712 | pmc = 4394036 | doi = 10.1016/j.celrep.2015.03.012 }}
92. ^{{cite journal | vauthors = Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC | title = Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma | journal = Clinical Cancer Research | volume = 18 | issue = 17 | pages = 4669–81 | date = September 2012 | pmid = 22806876 | pmc = 4456190 | doi = 10.1158/1078-0432.CCR-12-0779 }}
93. ^{{cite journal | vauthors = Shono Y, Tuckett AZ, Liou HC, Doubrovina E, Derenzini E, Ouk S, Tsai JJ, Smith OM, Levy ER, Kreines FM, Ziegler CG, Scallion MI, Doubrovin M, Heller G, Younes A, O'Reilly RJ, van den Brink MR, Zakrzewski JL | title = Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses | journal = Cancer Research | volume = 76 | issue = 2 | pages = 377–89 | date = January 2016 | pmid = 26744524 | doi = 10.1158/0008-5472.CAN-14-2814 | pmc = 4715937 }}
94. ^{{cite journal | vauthors = Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K | title = Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues | journal = Journal of Medicinal Chemistry | volume = 51 | issue = 18 | pages = 5780–8 | date = September 2008 | pmid = 18729348 | doi = 10.1021/jm8006245 }}
95. ^{{cite web | url = http://www.rfdn.org/inflammaging3.html | title = Role of RCP006 as an anti-inflammatory agent | work = | publisher = Roskamp Institute | accessdate = 2011-09-06 }}
96. ^{{cite journal | vauthors = Kolati SR, Kasala ER, Bodduluru LN, Mahareddy JR, Uppulapu SK, Gogoi R, Barua CC, Lahkar M | title = BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-κB pathway | journal = Environmental Toxicology and Pharmacology | volume = 39 | issue = 2 | pages = 690–9 | date = March 2015 | pmid = 25704036 | doi = 10.1016/j.etap.2015.01.019 }}
97. ^{{cite journal | vauthors = Kumar A, Negi G, Sharma SS | title = Suppression of NF-κB and NF-κB regulated oxidative stress and neuroinflammation by BAY 11-7082 (IκB phosphorylation inhibitor) in experimental diabetic neuropathy | journal = Biochimie | volume = 94 | issue = 5 | pages = 1158–65 | date = May 2012 | pmid = 22342224 | doi = 10.1016/j.biochi.2012.01.023 }}
98. ^{{cite journal | vauthors = Tanaka K, Yamaguchi T, Hara M | title = Iguratimod for the treatment of rheumatoid arthritis in Japan | journal = Expert Review of Clinical Immunology | volume = 11 | issue = 5 | pages = 565–73 | date = May 2015 | pmid = 25797025 | doi = 10.1586/1744666X.2015.1027151 }}

Discovery